SLS VENTURE

Copenhagen, Denmark, 20 June 2005 - Symphogen A/S has named Paul Rohricht as Vice President of Business Development. This appointment reflects Symphogen’s focus to partner and bring to market its pioneering recombinant human polyclonal antibodies, known as symphobodies.

In his role, Mr. Rohricht will be responsible for worldwide business development for Symphogen’s product portfolio consisting of therapeutic symphobodies Sym001 (anti-rhesus D), Sym002 (anti-VIG), Sym 003 (anti-RSV), and Sym004 (anti-cancer). Further he will be instrumental in establishing research collaborations and licensing deals for the company’s proprietary technologies, Symplexä, one of the most powerful platforms available for the discovery and identification of either monoclonal or polyclonal drug leads and Sympressä, a mammalian expression platform for the manufacturing of target-specific fully human recombinant polyclonal antibodies.

“Symphogen will greatly benefit from Paul’s extensive business development experience and we are pleased to welcome him as a member of the management team,” said Dr. Kirsten Drejer, CEO, Symphogen. “Paul has proven himself at developing products and partnerships as well as finding new market opportunities, which will be most useful as we advance our products through clinical trials to market.”

Rohricht joins Symphogen from Revivicor, Inc., where he was co-founder and Vice President of Corporate Development. In this role he secured financing, negotiated in-licensing of key intellectual property estate, and developed and executed the out-licensing strategy for products developed by the company, and secured several government grants. Prior to Revivicor, Rohricht held the role of Vice President of Business Development at PPL Therapeutics. In addition to licensing, Rohricht has experience in mergers and acquisitions, has started and run his own business development consulting company as well held several other business development and senior sales roles at biotechnology companies throughout his fifteen year career.

Rohricht received his Master’s degrees in Science and Engineering and Technology Management/MBA from the University of Pennsylvania (School of Engineering/Wharton School of Business), and his bachelor’s degree in biology from St. Olaf Collage. He has also served in the past as a member of the adjunct faculty at Alvernia College as an instructor in its MBA program, teaching Corporate Finance, Management Finance, Leadership, and International Marketing.

About Symphogen

Symphogen A/S is a biotechnology company pioneering therapeutic products based on natural human antibodies for the treatment and prevention of human disease. Using its proprietary technologies, Symphogen aims to develop and eventually market unique antibody-based products that mimic the diversity, affinity, and specificity of the natural human immune system. Antibody drug candidates are generated using the Symplex^TM technology and the selected lead candidate may be polyclonal or monoclonal, depending on the nature of the target. The Company applies its proprietary expression platform, the Sympress^TM technology, for consistent manufacturing of recombinant polyclonal antibody compositions. Symphobodies offer a number of advantages over current plasma-derived immunoglobulins and monoclonal antibody therapies for the treatment of diseases characterized by complex target antigens, such as those found in infectious diseases, allergy, transplant rejection, and cancer. For more information, please visit www.symphogen.com.

For more information about Symphogen A/S please contact:
Kirsten Drejer, CEO. Symphogen A/S: +45 45 26 50 59, kd@symphogen.com
John Haurum, CSO, Symphogen A/S: +45 45 26 50 70, jh@symphogen.com
Katja Stout/Ashley Lilly, Northbank Communications: +44 207 886 8150, a.lilly@northbankcommunications.com


	SYMPHOGEN A/S APPOINTS PAUL ROHRICHT AS VICE PRESIDENT OF BUSINESS DEVELOPMENT Copenhagen, Denmark, 20 June 2005 - Symphogen A/S has named Paul Rohricht as Vice President of Business Development. This appointment reflects Symphogen’s focus to partner and bring to market its pioneering recombinant human polyclonal antibodies, known as symphobodies. In his role, Mr. Rohricht will be responsible for worldwide business development for Symphogen’s product portfolio consisting of therapeutic symphobodies Sym001 (anti-rhesus D), Sym002 (anti-VIG), Sym 003 (anti-RSV), and Sym004 (anti-cancer). Further he will be instrumental in establishing research collaborations and licensing deals for the company’s proprietary technologies, Symplexä, one of the most powerful platforms available for the discovery and identification of either monoclonal or polyclonal drug leads and Sympressä, a mammalian expression platform for the manufacturing of target-specific fully human recombinant polyclonal antibodies. “Symphogen will greatly benefit from Paul’s extensive business development experience and we are pleased to welcome him as a member of the management team,” said Dr. Kirsten Drejer, CEO, Symphogen. “Paul has proven himself at developing products and partnerships as well as finding new market opportunities, which will be most useful as we advance our products through clinical trials to market.” Rohricht joins Symphogen from Revivicor, Inc., where he was co-founder and Vice President of Corporate Development. In this role he secured financing, negotiated in-licensing of key intellectual property estate, and developed and executed the out-licensing strategy for products developed by the company, and secured several government grants. Prior to Revivicor, Rohricht held the role of Vice President of Business Development at PPL Therapeutics. In addition to licensing, Rohricht has experience in mergers and acquisitions, has started and run his own business development consulting company as well held several other business development and senior sales roles at biotechnology companies throughout his fifteen year career. Rohricht received his Master’s degrees in Science and Engineering and Technology Management/MBA from the University of Pennsylvania (School of Engineering/Wharton School of Business), and his bachelor’s degree in biology from St. Olaf Collage. He has also served in the past as a member of the adjunct faculty at Alvernia College as an instructor in its MBA program, teaching Corporate Finance, Management Finance, Leadership, and International Marketing. About Symphogen Symphogen A/S is a biotechnology company pioneering therapeutic products based on natural human antibodies for the treatment and prevention of human disease. Using its proprietary technologies, Symphogen aims to develop and eventually market unique antibody-based products that mimic the diversity, affinity, and specificity of the natural human immune system. Antibody drug candidates are generated using the Symplex^TM technology and the selected lead candidate may be polyclonal or monoclonal, depending on the nature of the target. The Company applies its proprietary expression platform, the Sympress^TM technology, for consistent manufacturing of recombinant polyclonal antibody compositions. Symphobodies offer a number of advantages over current plasma-derived immunoglobulins and monoclonal antibody therapies for the treatment of diseases characterized by complex target antigens, such as those found in infectious diseases, allergy, transplant rejection, and cancer. For more information, please visit www.symphogen.com. For more information about Symphogen A/S please contact: Kirsten Drejer, CEO. Symphogen A/S: +45 45 26 50 59, kd@symphogen.com John Haurum, CSO, Symphogen A/S: +45 45 26 50 70, jh@symphogen.com Katja Stout/Ashley Lilly, Northbank Communications: +44 207 886 8150, a.lilly@northbankcommunications.com